Juno in the press

SAN DIEGO--(PRWEB) January 30, 2023-- Juno Diagnostics™, Inc. (JunoDx™), a women’s health company focused on improving equitable access to prenatal care led by industry experts, announced today that its co-founder and CEO, Dirk van den Boom, has been accepted into the Forbes Business Council, an invitation-only community for successful business owners and leaders worldwide.

January 24, 2023 --Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced it will participate at the Precision Medicine World Conference (PMWC), held January 25-27, 2023, in Santa Clara, CA.

January 9, 2023 --Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced the expansion of its product portfolio with the launch of Juno Hazel™ Plus, a non-invasive prenatal screening (NIPS, also known as NIPT) solution enabled through finger-prick amounts of blood, and the creation of an Early Access Program (EAP). 

January 5, 2023 --Juno Diagnostics™ (JunoDx™),  a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced the formation of its Clinical Advisory Board (“CAB”). The high-profile board is comprised of leading industry experts in women’s health, reproductive medicine, and patient-centered prenatal care, which will further the Company’s ability to support a broader community before, during, and after their pregnancy journeys.

December 12, 2022 --Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced that JunoDx’s Founder and Chief Executive Officer, Dirk van den Boom, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 2:00 PM. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41^st Annual HealthCare Conference.

NEW YORK – With the recent launch of its Hazel finger prick-based
prenatal genetic screening test, Juno Diagnostics aims to reduce barriers to access in the noninvasive prenatal testing (NIPT) market. The tests, which screen for trisomies 13, 18, and 21, require a physician's order but blood collection can be performed at home, removing the need for phlebotomy, which is both more invasive and inconsistently available, particularly to patients in rural areas.

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced the launch of Juno Hazel™, a non-invasive prenatal screening (NIPS) solution enabled from finger-prick amounts of blood. The Juno Hazel™ test breaks through one of the most significant barriers to access for genetic testing by leveraging JunoDx’s proprietary Sample Collection Kit.

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participation in the Credit Suisse 31^st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA. 

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced the addition of Gina Grayum to its commercial leadership team. Ms. Grayum brings more than a decade of diagnostics sales and management experience to JunoDx™, most recently as U.S. Sales Director, Women's Health for Invitae Corporation.

We are excited to announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations. Mr. Whitson is a well-recognized veteran in the genetics and molecular diagnostics fields who brings more than two decades of healthcare experience to JunoDx.

Juno Diagnostics™, Inc. (JunoDx™), a women's health company focused on improving equitable access to prenatal care led by industry experts, will be exhibiting at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM) in San Diego, May 6-8, 2022, at Booth #1023.

– Reproductive health pioneers developing genetic testing solutions to dramatically improve access to prenatal care for all women in all geographies – – Experienced leadership team developed and launched the...